/ /

  • linkedin
  • Increase Font
  • Sharebar

    Santen to acquire InnFocus, developer of glaucoma drainage implant

    Santen Pharmaceutical will soon acquire InnFocus, developer of a glaucoma implant device (InnFocus Microshunt), for $225 million, according to a definitive agreement from the two companies.

    The device is being developed to lower and sustain IOP for treatment of primary open-angle glaucoma (POAG). International clinical trials have shown the implant is effective when used alone, as well as in conjunction with cataract surgery, according to InnFocus.Courtesy of InnFocus Inc.

    The implant device has also received CE Mark in Europe.

    The company is in the process of conducting late-stage clinical studies in the United States, as well as in Europe, in advance of its planned Pre-Market Approval (PMA) application to the FDA in the near future.

    More FDA news: FDA approves one-of-a-kind IOL with extended range of vision

    “The InnFocus MicroShunt was developed to be the world’s first minimally invasive stand-alone procedure for mild, moderate, and severe-stage POAG. In addition to reducing IOP, the MicroShunt does not require simultaneous cataract removal, unlike many micro-invasive glaucoma surgery (MIGS) technologies,” said Randy Lindholm, executive chairman of the board of InnFocus.  “The InnFocus team is very pleased to be joining Santen and its global effort to address this growing and important segment of the ophthalmic market.”

    The companies also noted the acquisition is subject to conditions under the Hart-Scott-Rodino Antitrust Improvements Act of the United States.

    More news: Shire's FDA-approved drug ends dry eye treatment drought

    Additional details about the acquisition are planned to be announced on Aug. 2, 2016.

    “With this acquisition, Santen will strengthen our glaucoma pipeline and stay at the forefront of innovation in ophthalmology,” said Akira Kurokawa, president and chief executive officer of Santen. “This agreement is in line with our long-term vision to become a specialized pharmaceutical company with a global presence. I am truly excited about the MicroShunt as a new and effective treatment option that should significantly improve patient outcomes.”

    More about the device

    Jolie Higazi
    Jolie is the Content Specialist for Ophthalmology Times. She can be reached at [email protected]

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results